<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686020</url>
  </required_header>
  <id_info>
    <org_study_id>1152014</org_study_id>
    <nct_id>NCT03686020</nct_id>
  </id_info>
  <brief_title>Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study)</brief_title>
  <acronym>CYFRA21-1</acronym>
  <official_title>Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to measure serum and salivary CYFRA21-1 levels using enzyme linked
      immunosorbent assay (ELISA) in patients with oral malignancy, oral potentially malignant
      lesions, and control subjects to evaluate the potential of CYFRA21-1 as a diagnostic marker
      for malignant transformation in potentially malignant oral mucosal lesions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity and specificity of serum and salivary CYFRA21-1 as a diagnostic marker in oral cancer</measure>
    <time_frame>one year</time_frame>
    <description>diagnostic accuracy in terms of sensitivity and specificity of serum and salivary CYFRA21-1 in differentiating between oral malignancy and oral potential malignant lesions in order to be able to early diagnose malignant changes in oral lesions.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Oral Potentially Malignant Lesions</condition>
  <condition>Oral Cancer</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <description>participants suffering from oral potentially malignant lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <description>participants suffering from diagnosed oral malignant lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <description>healthy participants who are systemically free, non-smokers, and not suffering from any oral mucosal lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Enzyme Linked Immunosorbent assay (ELISA)</intervention_name>
    <description>measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Egyptian population
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        participants will be divided into 3 groups:

          -  Group I: patients suffering from oral potentially malignant lesions (PML) as defined
             by World Health Organization.

          -  Group II: patients suffering from diagnosed oral malignant lesions

          -  Group III: healthy subjects who are systemically free, non-smokers, and not suffering
             from any oral mucosal lesions.

        Exclusion Criteria:

          -  Subjects taking any drugs inducing any changes that could affect the salivary flow.

          -  Pregnant females.

          -  Subjects have any allergies, infectious diseases or active dental abscesses during one
             month before saliva sampling.

          -  Patients receiving any drugs related to the oral lesions in the past 6 month prior to
             sample collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Salsabeel A Mahmoud</last_name>
    <phone>00201222343488</phone>
    <email>salsabeel_ali@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Basma A Zakaria</last_name>
    <email>basma.abdelalim@dentistry.cu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salsabeel Ali Mahmoud, MD</last_name>
      <phone>01222343488</phone>
      <email>salsabeel_ali@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Rajkumar K, Ramya R, Nandhini G, Rajashree P, Ramesh Kumar A, Nirmala Anandan S. Salivary and serum level of CYFRA 21-1 in oral precancer and oral squamous cell carcinoma. Oral Dis. 2015 Jan;21(1):90-6. doi: 10.1111/odi.12216. Epub 2013 Dec 30.</citation>
    <PMID>24304502</PMID>
  </reference>
  <reference>
    <citation>Alkotyfan K, Wiegand S, MÃ¼ller HH, Windfuhr JP, Werner JA, Sesterhenn AM. Cyfra 21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharynx. Anticancer Res. 2010 Jun;30(6):2291-6.</citation>
    <PMID>20651382</PMID>
  </reference>
  <reference>
    <citation>Awasthi N. Role of salivary biomarkers in early detection of oral squamous cell carcinoma. Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):464-468. doi: 10.4103/IJPM.IJPM_140_16.</citation>
    <PMID>29323056</PMID>
  </reference>
  <reference>
    <citation>Gualtero DF, Suarez Castillo A. Biomarkers in saliva for the detection of oral squamous cell carcinoma and their potential use for early diagnosis: a systematic review. Acta Odontol Scand. 2016;74(3):170-7. doi: 10.3109/00016357.2015.1110249. Epub 2015 Nov 18. Review.</citation>
    <PMID>26577643</PMID>
  </reference>
  <reference>
    <citation>Malhotra R, Urs AB, Chakravarti A, Kumar S, Gupta VK, Mahajan B. Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma. Tumour Biol. 2016 Jul;37(7):9263-71. doi: 10.1007/s13277-016-4809-4. Epub 2016 Jan 15.</citation>
    <PMID>26779624</PMID>
  </reference>
  <reference>
    <citation>Mortazavi H, Baharvand M, Mehdipour M. Oral potentially malignant disorders: an overview of more than 20 entities. J Dent Res Dent Clin Dent Prospects. 2014 Winter;8(1):6-14. doi: 10.5681/joddd.2014.002. Epub 2014 Mar 5. Review.</citation>
    <PMID>25024833</PMID>
  </reference>
  <reference>
    <citation>Wang YX, Hu D, Yan X. Diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci. 2013 Sep;17(17):2383-9. Review.</citation>
    <PMID>24065233</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Salsabeel Ali Mahmoud</investigator_full_name>
    <investigator_title>PHD postgraduate student</investigator_title>
  </responsible_party>
  <keyword>Oral potentially malignant lesions</keyword>
  <keyword>Oral cancer</keyword>
  <keyword>salivary CYFRA21-1</keyword>
  <keyword>serum CYFRA21-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

